• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 75
  • 32
  • 16
  • 16
  • 10
  • 5
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 189
  • 44
  • 41
  • 38
  • 30
  • 26
  • 23
  • 23
  • 22
  • 20
  • 16
  • 15
  • 14
  • 14
  • 13
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
71

Coopération privilégiée entre le microenvironnement stromal et les variants autonomes du récepteur des androgènes dans le cancer de la prostate / Specific cooperation between stromal microenvironment and constitutively active androgen receptor variants in prostate cancer

Asmane, Irène 20 July 2015 (has links)
Malgré le rôle des variants constitutivement actifs du récepteur des androgènes (RA) et du stroma tumoral dans le cancer de la prostate résistant à la castration (CRPC), leurs relations restent inconnues. Nous rapportons l’impact de l’interleukine-6 (IL-6) sécrétée par les cellules stromales prostatiques (PrSC) sur les cellules épithéliales tumorales prostatiques exprimant les variants autonomes du RA. Le milieu de culture conditionné par les PrSC (CMPrSC) contenait des taux élevés d’IL-6 et induisait une augmentation de l’activité transcriptionnelle de STAT3 dans les LNCaP et C4-2b exprimant le variant RAQ640X, via une activation de pY705-STAT3. Cette activité de STAT3 était inhibée par la neutralisation de l’IL-6. L’analyse par mRNA array et RT-qPCR a mis en évidence un profil transcriptomique spécifique lié à l’expression du RAQ640X et à l’exposition au CMPrSC, impliquant les fonctions de motilité, d’invasion et de migration cellulaires, et l’expression de gènes favorisant la dissémination métastatique. Ainsi, nos résultats illustrent une coopération épithélio-stromale «privilégiée» en présence de variants autonomes du RA, impliquée dans la progression tumorale. / Constitutively active androgen receptor (AR) variants and stromal microenvironment are involved in castration resistant prostate cancer (CRPC), but their relationship remains unknown. We describe the effects of interleukin-6 (IL6) secreted from prostate stromal fibroblast cells (PrSC) towards prostate epithelial cancer cells expressing constitutively active AR variants. Conditioned culture medium from PrSC (CMPrSC) contained high levels of IL-6 and led to an increased STAT3 transcriptional activity in LNCaP and C4-2b cells expressing the ARQ640X variant, through pY705-STAT3 activation. This STAT3 activity was significantly diminished with neutralizing antibody anti-IL6. Gene expression analysis using mRNA array and RT-qPCR highlighted a specific transcriptional profile related to ARQ640X expression and PrSC exposure, resulting in cellular motility, invasion and cellular migration, and IL-6 genes expression promoting metastatic dissemination. Overall, our data emphasize a “preferred” epithelio-stromal cooperation when expressing constitutive active RA variants, which contributes to tumor progression.
72

ROTAS DE SINALIZAÇÃO NA DIVERGÊNCIA FOLICULAR E LUTEÓLISE EM BOVINOS / SIGNALING PATHWAYS DURING FOLLICULAR DEVIATION AND LUTEOLYSIS IN CATTLE

Rovani, Monique Tomazele 12 September 2014 (has links)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / It is well established that locally produced factors exert pivotal roles during dominant follicle selection, oocyte maturation, ovulation and luteolysis. However, the identification of these factors and pathways involved in these processes are not yet established. In the present study, we focused on the in vivo bovine models to study reproductive physiology, which were used to identify receptors and intracellular signaling pathways involved in follicle selection and luteolysis. In the first study, it was reviewed the in vivo models used in our lab, describing and discussing the different bovine models and techniques currently used to study ovarian physiology in this mono-ovulatory specie. In a second study, it was evaluated the expression of estrogen receptors (ESRs) before (day 2 of follicular wave), during (day 3) and after (day 4) follicular deviation in cattle. ESR1 and ESR2 transcripts levels were higher in dominant (F1) than subordinate (F2) follicle after follicular deviation. FSH treatment maintained mRNA levels of both ESR1 and ESR2 in F2 follicles at similar levels observed in F1 follicles. Intrafollicular injection of 100 μM fulvestrant (an antagonist of ESRs) inhibited follicular growth and decreased CYP19A1 mRNA levels. Transcript levels of both ESR1 and ESR2 were not affected by fulvestrant injection. In the third study, our objective was to demonstrate the role of the transcription factor signal transducer and activator of transcription 3 (STAT3) and the nuclear receptor 5A2 (NR5A2) in luteolysis. Luteal and blood samples were collected from separate groups of cows on Day 10 of the estrous cycle 0, 2, 12, 24, and 48 hours after prostaglandin F2 alpha (PGF) treatment. Serum progesterone concentrations decreased (P < 0.05) within 2h and the histological examination of the corpus luteum at 24 and 48h after PGF treatment confirmed functional and morphological luteolysis, respectively. The abundance of STAR mRNA and protein decreased at 12h after PGF treatment. The abundance of NR5A2 mRNA and protein decreased (P < 0.05) at 12 and 24h post-PGF, respectively. Levels of STAT3 mRNA remained constant (P > 0.05) throughout the time-points evaluated. However, the abundance of phosphorylated isoform of STAT3, normalized to total STAT3, increased reaching a peak at 12h and remaining high until 48h after PGF treatment. In conclusion, bovine in vivo models provide a valuable system to study reproductive events under physiological endocrine environment while keeping intact the communication between follicular cells through autocrine and paracrine signaling, without the need to perform ovariectomy or euthanaze the animals. Our results suggest that both ESR1 and ESR2 are regulated during follicular deviation and dominance and in response to FSH treatment in cattle, ESRs are required for normal gene expression and development of the dominant follicle. PGF treatment results in decreased expression of the nuclear receptor NR5A2 and activation of STAT3 by phosphorylation in bovine luteal cells. / É bem estabelecido que fatores produzidos localmente exercem papel essencial durante a seleção do folículo dominante, maturação oocitária, ovulação e luteólise. No entanto, os fatores e vias envolvidas nestes processos não estão totalmente estabelecidos. No presente estudo, enfatizou-se o uso de modelos bovinos in vivo para o estudo da fisiologia reprodutiva, sendo aqui utilizados para identificar receptores e vias de sinalização intracelular envolvidas na seleção do folículo e luteólise. No primeiro estudo, revisaram-se os modelos in vivo utilizados em nosso laboratório, descreveram-se e discutiram-se os diferentes modelos em bovinos e técnicas atualmente utilizadas para estudar fisiologia ovariana nesta espécie monovulatória. Em um segundo estudo, avaliou-se a expressão de receptores de estradiol (ESRS) antes (dia 2 da onda folicular), durante (dia 3) e após (dia 4) a divergência folicular em bovinos. Os níveis dos transcritos ESR1 e ESR2 foram maiores no folículo dominante (F1) que no subordinado (F2) após a divergência folicular. O tratamento com FSH manteve os níveis de RNAm de ambos ESR1 e ESR2 nos folículos F2 em níveis semelhantes aos observados em folículos F1. A injeção intrafolicular de 100 uM de fulvestrant (um antagonista de ESRs) inibiu o crescimento folicular e causou uma diminuição dos níveis de RNAm de CYP19A1. Os níveis de transcritos, tanto para ESR1 e ESR2, não foram afetados pela injeção de fulvestrant. Num terceiro estudo, o nosso objetivo foi demonstrar o papel do Transdutor de sinais e ativador de transcrição 3 (STAT3) e do receptor nuclear 5A2 (NR5A2) na luteólise. Amostras de corpo lúteo (CL) e sangue foram coletadas dos grupos de vacas 0, 2, 12, 24 e 48 horas após o tratamento com prostaglandina F2 alpha (PGF) no dia 10 do ciclo estral. A concentração de progesterona sérica diminuiu (P < 0.05) em 2 horas e o exame histológico do CL às 24h e 48h após o tratamento com PGF confirmou a ocorrência de luteólise funcional e morfológica, respectivamente. A abundância de RNAm e proteína de STAR diminuiu às 12h após o tratamento com PGF. A abundância de RNAm e proteína de NR5A2 diminuiu (P < 0.05) às 12 e 24 horas pós-PGF, respectivamente. Os níveis de RNAm de STAT3 permaneceram constantes (P> 0.05) ao longo do tempo avaliado. No entanto, a abundância da isoforma fosforilada de STAT3, normalizados para STAT3 total, aumentou, atingindo um pico às 12h e permaneceu elevada até 48h após o tratamento com PGF. Em conclusão, os modelos bovinos in vivo fornecem um sistema valioso para estudar os eventos reprodutivos sob ambiente fisiológico, mantendo intacta a comunicação entre as células foliculares através de sinalização autócrina e parácrina, reduzindo a necessidade de realizar ovariectomia ou realizar a eutanásia dos animais. Nossos resultados sugerem que tanto ESR1 como ESR2 são regulados durante a divergência e dominância folicular em bovinos e em resposta ao tratamento com FSH, e ESRs são necessários para a expressão gênica e para o desenvolvimento do folículo dominante. O tratamento com PGF resulta em diminuição da expressão do receptor nuclear NR5A2 e ativação de STAT3 por fosforilação em células luteais bovinas.
73

Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine suppresseur de tumeur p14ARF dans les adénocarcinomes pulmonaires / Control of EGFR-L858R oncogenic signaling pathway by the p14ARF tumor suppressor in lung adenocarcinoma.

Ozenne, Peggy 29 November 2011 (has links)
Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine suppresseur de tumeur p14ARF dans les adénocarcinomes pulmonaires. Le récepteur à l'EGF (EGFR) est un oncogène puissant impliqué dans le développement des cancers du poumon. Dans ces cancers, la présence de mutations activatrices de l'EGFR (majoritairement L858R et Del19) est un facteur prédictif de réponse aux agents pharmacologiques qui ciblent spécifiquement ce récepteur (EGFR-TKI). Cependant, l'association entre réponse thérapeutique et mutation est plus complexe que prévue, soulignant la nécessité d'approfondir la compréhension des mécanismes moléculaires impliqués dans développement de ces cancers. Nous avons précédemment montré que la quasi-totalité des tumeurs pulmonaires avec des mutations activatrices de l'EGFR présente une expression faible ou indétectable de la protéine suppressive de tumeur p14ARF. Ces résultats nous ont conduites à émettre l'hypothèse que l'expression de p14ARF était un frein essentiel à l'expansion clonale de ces cellules. Nous décrivons pour la première fois une relation fonctionnelle entre p14ARF et du mutant L858R de l'EGFR dans laquelle p14ARF inhibe la croissance de cellules exprimant ce mutant en induisant leur apoptose. Les effets suppresseurs de tumeur de p14ARF impliquent une fonction pro-apoptotique originale de STAT3 qui conduit à l'inhibition de l'expression de la protéine anti-apoptotique Bcl-2. De plus, nous montrons que les cellules EGFR-L858R maintiennent leur avantage de croissance en inhibant l'expression de p14ARF et la signalisation pro-apoptotique STAT3/Bcl-2 qui en découle. Nos résultats identifient également p14ARF comme une nouvelle cible transcriptionnelle de STAT3, mettant ainsi en évidence une boucle de rétrocontrôle positif entre ces deux protéines qui pourrait entretenir la signalisation pro-apoptotique médiée par STAT3. Sur la base de ces résultats, nous suggérons que la réactivation de la voie p14ARF/STAT3/Bcl-2 pourrait être une nouvelle stratégie thérapeutique dans le traitement de ces cancers. / Control of EGFR-L858R oncogenic signaling pathway by the p14ARF tumor suppressor in lung adenocarcinoma. The EGF receptor (EGFR) is a strong oncogene involved in lung carcinogenesis. In these cancers, sensitivity to inhibitors of the EGFR tyrosine kinase activity (EGFR-TKI) has been shown to be related to the presence of activating mutations in the TK domain of EGFR (mainly L858R and Del19). However, the association between mutations and responsiveness to EGFR-TKI based treatment is more complex than previously envisioned, underlying the pressing need to study thoroughly the molecular mechanisms of lung cancer growth. We previously showed that almost all lung cancer with EGFR activated mutations has very low or undetectable levels of the p14ARF tumor suppressor protein. These results led us to postulate that expression of p14ARF is an efficient break against clonal proliferation of these cells. We report for the first time a relationship between p14ARF and mutant EGFR-L858R in which p14ARF inhibits the growth of EGFR-L858R expressing cells by inducing apoptosis. The p14ARF tumor suppressor effects involve an original STAT3 pro-apoptotic function that drives the inhibition of the anti-apoptotic Bcl-2 protein. Moreover, we show that the EGFR-L858R mutant maintains their survival and proliferation characteristics by inhibiting p14ARF expression and consequently the STAT3/Bcl-2 pro-apoptotic pathway. Our results also identify p14ARF as a new transcriptional target of STAT3, therefore providing evidence of a positive feed-back loop that could maintain STAT3 pro-apoptotic pathway. Based on these data, we suggest that manipulation of this pathway could be a therapeutic strategy for lung cancer treatment.
74

Estudo da expressão proteica da via HGF/c-Met/STAT3 no carcinoma diferenciado da tiroide / Study of protein expression of HGF/c-Met/STAT3 pathway in differentiated thyroid carcinoma

Rocha, Angélica Gomes, 1989- 26 August 2018 (has links)
Orientadores: Laura Sterian Ward, Antônio Hugo José Fróes Marques Campos / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-26T01:02:11Z (GMT). No. of bitstreams: 1 Rocha_AngelicaGomes_M.pdf: 1644333 bytes, checksum: e3503fb6e2c8209f7a6696df111d6a78 (MD5) Previous issue date: 2014 / Resumo: Marcadores de malignidade, especialmente capazes de distinguir lesões de padrão folicular, que sejam de fácil implantação na rotina do diagnóstico de nódulos tireoidianos, continuam sendo extremamente necessários, dado o crescente aumento de nódulos tireoidianos diagnosticados nos últimos anos. A via HGF/c-Met/STAT3 está relacionada com desenvolvimento e progressão tumoral, sendo que a expressão de c-Met, HGF e de STAT3 foram descritas em grande parte dos carcinomas papilíferos de tireoide (CPT), mas não em tecido tireoidiano normal, sugerindo sua relação com o desenvolvimento e progressão do CPT. Para avaliar a utilidade da expressão proteica de c-Met, HGF, STAT3, e de sua proteína fosforilada (pSTAT3) no diagnóstico e no prognóstico de pacientes com nódulos tireoidianos, analisamos 356 tecidos tireoidianos, sendo 153 carcinomas papilíferos (CPT), dos quais 95 eram clássicos (CPC), 47 carcinomas papilíferos variante folicular (CPVF), e 11 carcinomas papilíferos de células altas (CPCA); 34 carcinomas foliculares (CFT), 34 adenomas foliculares (AF), 124 bócios e 11 tecidos normais. Todos os pacientes foram tratados e acompanhados de acordo com um mesmo protocolo padrão por 1-10 anos (Mo=5 anos). Áreas representativas do tecido foram selecionadas para a construção de uma lâmina de tissue microarray (TMA) que foi submetida à técnica de imunoistoquímica e analisada pelo score de Allred. A expressão citoplasmática de c-Met foi capaz de diferenciar nódulos malignos de benignos (p<0,0001, sensibilidade 86%, especificidade 76%, VPP 77%, VPN 86%); CPT de CF (p=0,0003, sensibilidade 96%, especificidade 31%, VPP 87%, VPN 63%); variante folicular de CPT de CF (p=0,0232 sensibilidade 93%, especificidade 31%, VPP 66%, VPN 77%); assim como variante folicular de CPT de AF (p=0,0003, sensibilidade 93%, especificidade 50%, VPP 68%, VPN 87%). Além disso, a expressão de c-Met se correlacionou com tireoidite (p<0,0001) e multifocalidade (p=0,0028), mas não com presença de cápsula, invasão, tamanho do tumor, estadiamento TNM, e presença de metástase no diagnóstico e na evolução. A expressão nuclear de STAT3 diferenciou os nódulos benignos dos malignos (p<0,0001, sensibilidade 83%, especificidade 74%, VPP 75%, VPN 83%); CF de AF (p=0,0457, sensibilidade 80%, especificidade 52%, VPP 65%, VPN 71%); bócios de CPT variante folicular (p<0,001, sensibilidade 89%, especificidade 65%, VPP 91%, VPN 60%); bócio de CF (p<0,0001, sensibilidade 89%, especificidade 80%, VPP 95%, VPN 60%); bócio de AF (p=0,0005, sensibilidade 89%, especificidade 80%, VPP 95%, VPN 60%). Além disso, a expressão de STAT3 se correlacionou com tireoidite (p=0,0095) e multifocalidade (p<0,0001), mas não com presença de cápsula, invasão, tamanho do tumor, estadiamento TNM, e presença de metástase no diagnóstico e na evolução. A expressão de pSTAT3 e HGF não auxiliou no diagnóstico dos nódulos, e tampouco se correlacionou com características de agressividade dos tumores. Conclui-se que as proteínas c-Met e STAT3 podem ser consideradas marcadores clínicos úteis na rotina de laboratórios, uma vez que foram capazes de diferenciar os nódulos malignos dos benignos, alguns tipos histológicos dos nódulos, além de se correlacionarem com fatores de agressividade dos tumores / Abstract: Malignancy markers, especially the ones that are capable of distinguishing follicular lesions and with easy deployment in the routine diagnosis of thyroid nodules are much needed, given the increasing number of thyroid nodules in recent years. The HGF/c-Met/STAT3 pathway is related to the development and progression of many types of cancers, and c-Met, HGF and STAT3 expression were described in most papillary thyroid carcinomas (PTC), but not in normal thyroid tissue, suggesting it is related with the development and progression of PTC. To evaluate the usefulness of c-Met, HGF, STAT3, and its phosphorylated form (pSTAT3) protein expression in the diagnosis and prognosis of patients with thyroid nodules, we analyzed 356 thyroid tissues, including 153 papillary carcinomas (PTC), 95 classical type, 47 follicular variants of papillary carcinoma, and 11 tall cells carcinomas; 34 follicular carcinomas (FC), 34 follicular adenomas (FA), 124 goiters and 11 normal tissues. All patients were treated and monitored according to the same standard protocol for 1-10 years (Mo = 5 years). Representative tissue areas were selected for the construction of a tissue microarray (TMA) which was subjected to immunohistochemistry and analyzed by the Allred score. The cytoplasmic expression of c-Met was able to differentiate malignant from benign nodules (p <0.0001, sensitivity 86%, specificity 76%, PPV 77%, 86% NPV); PTC from FCT (p = 0.0003, sensitivity 96%, specificity 31%, PPV 87%, 63% NPV); follicular variant of PTC from FCT (p = 0.0232 sensitivity 93%, specificity 31%, PPV 66%, NPV 77%); as well as follicular variant of CPT from FA (p = 0.0003, sensitivity 93%, specificity 50%, PPV 68%, 87% NPV). Furthermore, c-Met expression was correlated to the presence of thyroiditis (p<0.0001) and multifocality (p=0.0028), but not with the presence of capsule, invasion, tumour size, TNM staging, and metastasis at diagnosis or evolution of the disease. The nuclear expression of STAT3 differentiated benign from malignant nodules (p <0.0001, sensitivity 83%, specificity 74%, PPV 75%, NPV 83%); FCT from FA (p = 0.0457, sensitivity 80%, specificity 52%, PPV 65%, NPV 71%); goiter follicular variant of PTC (p <0.001, sensitivity 89%, specificity 65%, PPV 91%, 60% NPV); goiter from FCT (p <0.0001, sensitivity 89%, specificity 80%, PPV 95%, NPV 60%); goiter from FA (p = 0.0005, sensitivity 89%, specificity 80%, PPV 95%, NPV 60%). In addition, STAT3 expression was associated with thyroiditis (p=0.0095) and multifocality (p<0.0001), but not with the presence of capsule, invasion, tumour size, TNM staging, and metastasis at diagnosis or evolution of the disease. The expression of pSTAT3 and HGF did not help the diagnostic of nodules and was not correlated with any tumour characteristic of aggressiveness. We concluded that c-Met and STAT3 could be useful as molecular markers in laboratory routine, helping to differentiate malignant from benign nodules, and some histological types of nodules, and was also associated with some tumour characteristics of aggressiveness / Mestrado / Ensino em Saúde / Mestra em Clínica Médica
75

Expressão dos fatores LIF (Fator Inibitório de Leucemia), IL-6 (Interleucina-6), STAT-3 (Ativador de Transcrição-3) e telomerase em coriocarcinomas / Expression of LIF (Leukemia Inhibitory Factor), IL-6 (Interleukin-6), STAT-3 (Activator of Transcription-3) and telomerase in choriocarcinomas

Pietro, Luciana, 1981- 12 November 2013 (has links)
Orientadores: Liliana Aparecida Lucci de Angelo Andrade, Fatima Aparecida Böttcher-Luiz / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-24T02:59:06Z (GMT). No. of bitstreams: 1 Pietro_Luciana_D.pdf: 3492137 bytes, checksum: 723d823e8ddb16925da7aa8f48f22ea1 (MD5) Previous issue date: 2013 / Resumo: A invasão do endométrio pelo trofoblasto extraviloso é fundamental no desenvolvimento do feto e da placenta, processo este controlado por fatores ligados à atividade imunológica e hormonal que, quando alterada, pode resultar em interrupção da gestação e/ou geração das chamadas doenças trofoblásticas gestacionais. Em algumas situações, pode haver evolução para o coriocarcinoma, neoplasia maligna do trofoblasto, em que há evidências da atuação das moléculas ligadas ao processo de fusão celular e inflamação. Porém, os estudos neste tema são incipientes e inconclusivos. Considerando essas informações, o objetivo deste trabalho é estudar de forma comparativa a expressão das citocinas LIF, IL-6 e do ativador de transcrição STAT-3, além da telomerase, em material de aborto, de placenta normal a termo e de coriocarcinoma. Métodos: a expressão destas moléculas foi avaliada pelos métodos: imunoistoquímica (IHQ), imunofluorescência (IF), Western Blotting (WB) e Real-Time PCR (RT-PCR), em amostras de material de aborto, placenta normal a termo e coriocarcinoma (N=12 cada um). Os ensaios de WB e Real-Time PCR empregaram material a fresco de placenta normal a termo e seu cultivo celular e cultura da linhagem BeWo. Resultados: no material de aborto, as reações de IHQs evidenciaram expressão moderada de IL-6 em 58,4% dos casos e intensa de STAT-3 em 33,3%. Na placenta normal, observou-se intensa marcação de IL-6 em 50% e de STAT- 3 em 16,7% dos casos, enquanto que, no coriocarcinoma, houve expressão intensa de IL-6 em 50% e de STAT-3 em 75% dos casos. Por outro lado, as reações para LIF tiveram expressão nula em todos os três grupos. Pelo WB houve expressão proteica de IL-6 apenas no material fresco de placenta normal e ausência de expressão na sua cultura primária e na linhagem BeWo; LIF não foi expresso em todos os grupos estudados. STAT-3 foi detectado no citoplasma em todos os grupos, entretanto, a expressão nuclear da STAT-3 fosforilada (pSTAT-3) não foi observada na IF e nem pelo WB. Na análise gênica pelo RTPCR houve forte expressão de IL-6 e STAT-3 no material fresco de placenta normal e expressão muito fraca na cultura primária de placenta normal e na linhagem BeWo; a expressão de LIF foi muito fraca em todos os grupos. Apenas a linhagem BeWo demonstrou forte expressão gênica da telomerase, contrastando com a completa falta de expressão no material fresco de placenta normal e em sua cultura primária. Conclusão: A intensa expressão IHQ de IL-6 e STAT-3 no coriocarcinoma indica a atuação de ambas na carcinogênese. A expressão proteica de IL-6 no material fresco de placenta normal e sua ausência no material de cultura primária e na linhagem BeWo pode ser ocasionado pelo contato célula-a-célula nas culturas aderentes, inibindo o crescimento celular e, consequentemente, as vias de sinalização. A falta de expressão da pSTAT-3 tanto na IF como por WB demonstra que a via JAK-STAT está sendo desativada. A ausência de expressão de LIF, em todos os métodos estudados, sugere que esta citocina poderia estar sendo inibida por meio de proteínas SOCS3 ou, atuando, de modo indireto, na proliferação celular do coriocarcinoma. O aumento da atividade da telomerase nas células BeWo reforça sua relação com o fenótipo maligno e a aponta como um bom marcador para progressão da doença / Abstract: The invasion of the endometrium by extravillous trophoblast is a fundamental process in the growth of the fetus and placenta. The process is controlled by factors related to the immune and hormonal activity that, when changed, may result in termination of pregnancy and development of so-called gestational trophoblastic diseases. In some cases, changes can result in malignancy, in which some molecules play a role in cell fusion process and inflammation, although studies in this area are inconclusive. Considering this information, the study had the aim of investigating the expression of cytokines LIF, IL-6, STAT- 3 and the function of telomerase to understand their participation in abortion, in normal at term placenta and choriocarcinoma. Methods: The expression of the molecules was assessed by immunohistochemical assay (IHC), immunofluorescence (IF), Western Blotting (WB) and Real-Time PCR (RT - PCR) using fixed material from biopsies of abortions, normal at term placentas and choriocarcinoma along with fresh tissue of normal at term placenta and their primary culture and BeWo cell line. Paraffin embedded material used in IHC and IF assays were obtained from the Department of Pathology files. Tests of WB and Real-Time PCR employed fresh material, obtained from cell cultures of normal at term placenta and the BeWo line. Results: IHC reactions to abortion biopsies showed moderate staining for IL-6 in 58.4% of cases and intense for STAT-3 in 33.3 % of cases. In biopsies of normal placenta, there was intense reaction for IL-6 in 50% of cases, intense for STAT-3 in 16.7%; choriocarcinoma showed intense staining for IL- 6 in 50% of cases and also for STAT-3 in 75% of cases. On the other hand, LIF expression was missing in all three groups. WB analyses showed IL-6 protein in fresh material from normal placentas, but no expression in placenta primary cultures and BeWo line. LIF was absent in all groups. Cytoplasmic STAT-3 was observed in all groups, while the nuclear expression of phosphorylated STAT-3 was absent. On gene analyses a strong expression of IL-6 and STAT- 3 was observed from fresh normal placenta, but very weak expression in primary cultures of normal placenta and BeWo cell line. LIF expression was very weak in all groups. In regard to the gene expression of telomerase, it was strong in the BeWo line which contrasted with its complete lack of expression in fresh normal placenta and its primary culture. Conclusion: The high expression of IL-6 and STAT-3 in biopsies of choriocarcinoma indicates the role of both in tumor progression. Regarding protein expression, the presence of IL-6 in the material from fresh normal placenta, and its absence in primary culture and BeWo line may be caused by the cell-to-cell contact cultures by inhibiting cell growth and thus signaling pathways. However, the lack of expression of phosphorylated STAT-3 whether through IF or WB shows that its JAK-STAT pathway is inhibited. Lack of expression of the LIF suggests that it might be involved indirectly in choriocarcinoma cell proliferation or be inhibited by SOCS3 protein. Moreover, the increased telomerase activity of BeWo cells enhances their relation to the malignant phenotype and indicates a good marker for disease progression / Doutorado / Ciencias Biomedicas / Doutora em Ciências Médicas
76

Association oncogénique de Lyn et PAG dans les lymphomes B non Hodgkinien

Tauzin, Sébastien 09 September 2008 (has links)
Les lymphomes B non-Hodgkiniens sont caractérisés par des altérations génétiques à l’origine du syndrôme néoplasique. Dans ce travail, nous démontrons que l’association dans les microdomaines rafts de la membrane de Lyn, une kinase de la famille Src, avec l’adaptateur PAG, participe également au processus néoplasique. Dans les cellules B non-néoplasiques, Lyn et PAG sont des molécules impliquées dans la signalisation du récepteur des cellules B en réponse à une stimulation antigénique. Dans ce contexte, l’adaptateur PAG est décrit comme un inhibiteur de l’activité kinase de Lyn. Au contraire, dans les rafts des lymphomes B non-Hodgkiniens, nous avons mis en évidence que PAG retient la kinase Lyn sous une conformation active. Au sein des rafts, la kinase Lyn semble responsable de l’activation oncogénique de la voie de signalisation PI3K/Akt et de la voie de signalisation STAT3. L’inhibition pharmacologique et génétique de la kinase Lyn induit l’apoptose et l’inhibition de la prolifération de lignées cellulaires dérivées de lymphomes B non-Hodgkiniens. Ce résultat est révélateur d’une dépendance des lignées cellulaires à l’association oncogénique de Lyn avec PAG. Le ciblage thérapeutique du complexe Lyn/PAG constitue donc une opportunité pour le traitement des lymphomes B non-Hodgkiniens. / Non Hodgkin B lymphomas are caracterized by genetic alerations that condition their neoplastic development. In this work, we demonstrate that an association between the Src family kinase Lyn and the PAG adaptor in rafts is also involved in the neoplastic phenotype. In normal B cells, Lyn and PAG contribute to BCR signalling, where PAG functions as a Lyn kinase inihibitor. In contrast, we demonstrate that Lyn remains active when associated with PAG in B non Hodgkin lymphomas rafts. In those rafts, the Lyn kinase participates in the oncogenic activation of the PI3K/Akt and STAT3 signaling pathways. Pharmacologic and genetic inhibition of the Lyn kinase leads to apoptosis induction and proliferation inhibition of B non Hodgkin lymphoma cell lines. Our results reveal the dependence (or addiction) of these cell lines to the Lyn and PAG complex in rafts. The Lyn/PAG complex therefore constitutes an appropriate therapeutic target in certain non Hodgkin B lymphoma treatment.
77

Identification des biomarqueurs pour l’individualisation des traitements dans les cancers colorectaux / Identification of biomarkers for treatment's personalisation of the colorectal cancer

Dobi, Erion 20 November 2012 (has links)
Le cancer colorectal (CCR) est un problème majeur de santé publique. Les nouvelles stratégies thérapeutiques incluant les anticorps anti-EGFR ou anti-VEGF en association avec les chimiothérapies ont amélioré la survie des patients présentant un CCR métastatique. Nous avons évalué le rôle de nouveaux biomarqueurs pour individualiser les patients porteurs d’un CCR métastatique qui peuvent bénéficier d’un traitement par thérapies ciblées. Dans la première partie, nous avons démontré pour la première fois la valeur de pSTAT3 (STAT3 phosphorylé) comme biomarqueur prédictif pour sélectionner les populations porteuses d’un CCR métastatique qui pourraient bénéficier d’un traitement par anti-EGFR. Dans ce cadre nous avons publié les résultats de la valeur prédictive et pronostique de pSTAT3 chez 94 patients porteurs d’un CCR métastatique traités par cétuximab en 2ème ligne de traitement (Dobi et al, 2012).La probabilité d’avoir une réponse objective était de 13% chez les patients avec l’expression de STAT3 comparé à 41% chez les patients pSTAT3 négatif (p=0.02). Nous avons montré également l’impact négatif de pSTAT3 sur la durée de la survie sans progression (PFS) et de la survie globale (OS) des patients présentant un CCR métastatique. Ce résultat montre l’intérêt de STAT3 comme biomarqueur prédictif de traitement par anti-EGFR. Dans la deuxième partie, nous avons évalué l’impact en survie des facteurs d’angiogenèse complexe comme angiopoetin-2, syndecan-1 (CD138), FGL2. Dans ce cadre nous avons étudié une cohorte exploratoire à Besançon de patients porteurs d’un CCR métastatique, traitée par chimiothérapie cytotoxique et bévacizumab (anti-VEGF). Après la détermination des seuils de valeurs de chaque biomarqueurs dans le sérum de patients utilisant les courbes ROC, nous avons évalué l’impact négatif de score élevé d’angiopoetin-2 et CD138 en survie de ces patients. Nous avons également démontré l’impact négatif de la combinaison de 3 marqueurs combinés en termes d’OS et de PFS dans une cohorte de validation incluant 244 patients de Besançon, Tours et Dijon. / Despite the progress made in the management of metastatic colorectal cancer (mCRC), this disease remains a major health problem. Targeted therapies (anti-EGFR and anti-VEGF therapies) have improved the clinical outcomes achieved by conventional chemotherapy regimens. Half of the patients with K-RAS wild type colo-rectal cancer doen’t benefit from adding anti-EGFR to standard chemotherapy regimen. We decided to assess the clinical outcomes of anti-EGFR containing chemotherapy regimens in 94 patients with mCRC according to phosphorylated STAT3 (pSTAT) status. The probability of achieving an objective reponse was 13% among patients with positive nuclear expression of pSTAT3 compared with 41% for patients displaying pSTAT3 négative tumors (p=0.02). In a multivariate logistic regression model, high-grade skin rash, wild-type K-RAS status, and negative pSTAT3 status significantly improved time to progression (TTP) and overal survival (OS). These results underscore the impact of pSTAT3 on the clinical efficacy of anti-EGFR-containing chemotherapy regimens and support the prospective assessment of this biomarker. Inhibition of pSTAT3 in mCRCs might be a promising strategy to target chemotherapy-resistant cancer cells and should be assessed in association with anti-EGFR monoclonal antibodies. The second goal of our study was the identification of angiopoetin-2, syndecan1 (CD 138) and FGL2 as prognostic biomarquers of metastatic colorectal cancer patients. Plasma angiopoetin-2, FGL2 et CD 138 levels were mesured in 10 healthy volunteers, 13 patients with locally advanced CRC et 51 mCRC, received bevacizumab containing chemotherapy. Angiopoetin-2 and CD138 levels were significantly elevated in patients with mCRC compared with healthy controls. Amongst patients with mCRC, low pre-therapeutic plasma angiopoetin-2 and CD 138 levels were associated with a prolonged median progression-free survival (PFS) (p<0.01 and p=0.03 respectively), and overall survival (p<0.01 and p=0.02 respectively). PFS and OS was prolonged in patients with out or with only one detectable biomarker compared with patients with two or three high biomarker levels (p<0.01).
78

Validation fonctionnelle d’une nouvelle stratégie thérapeutique prévenant la dégénérescence et les troubles cognitifs associés dans des modèles murins de la Maladie d’Alzheimer / Functionnal validation of a new therapeutic strategy preventing degeneration and associated cognitive impairments in murine models of Alzheimer’s Disease

Garcia, Pierre 14 November 2011 (has links)
Aucun traitement de la maladie d’Alzheimer (MA) n’existe, justifiant le développement de stratégies thérapeutiques. La toxicité des oligomères solubles du peptide amyloïde β (Aβ) est centrale dans les pertes synaptiques et cellulaires précoces dans la maladie. Dans le cadre de cette hypothèse, nous proposons qu’empêcher ces effets puisse prévenir le déclin cognitif dans la MA. Les facteurs neurotrophiques sont de bons candidats pour prévenir la mort cellulaire mais nécessitent une application ciblée et continue. Nous avons utilisé la technologie d’encapsulation cellulaire pour produire des bioréacteurs implantables contenant des cellules C2C12 sécrétant le facteur neurotrophique ciliaire (CNTF). Notre objectif était d’établir la preuve du concept que la production à long terme de CNTF in situ dans le cerveau puisse prévenir les déficits cognitifs liés à l’Aβ.Nos études prouvent que le CNTF produit par les bioréacteurs prévient la cytotoxicité et l’apoptose induites par le peptide Aβ in vitro. La neuroprotection dépend de l’activation de la PI3-Kinase et du facteur STAT3. In vivo, l’implantation des bioréacteurs dans le cerveau prévient les troubles cognitifs induits par l’injection icv d’Aβ ou retarde leur apparition chez la souris Tg2576. Dans nos deux modèles précliniques de la MA, la protection comportementale est associée au maintien des protéines synaptiques dans l’hippocampe. Aussi, la production in situ de CNTF est une approche thérapeutique préventive efficace contre la toxicité et les déficits cognitifs liés à l’Aβ. Ces résultats suggèrent également que l’implantation de cellules encapsulées est un bon procédé pour délivrer des molécules thérapeutiques au cerveau / No cure against Alzheimer’s Disease (AD) exists yet, justifying the development of therapeutic strategies. Toxicity of soluble amyloid β peptide is a key-player in early synaptic and cellular loss in AD. According to this hypothesis, we propose that preventing Aβ peptide effects could prevent cogninitive decline in AD. Neurotrophic factors are good candidates to prevent cell death but require a targeted and continuous delivery. We used the cell encapsulation technology to produce graftable bioreactors that contain C2C12 cells secreting the Ciliary Neurotrophic factor (CNTF). Our goal was to realize the proof-of-concept that CNTF long term in situ delivery could prevent Aβ-induced cognitive decline.Our studies prove that bioreactor-produced CNTF prevents Aβ-induced cytotoxicity and apoptosis in vitro. Neuroprotection relies on PI3K and STAT3 activation. In vivo, bioreactor implantation in brain prevents cognitive impairment induced by Aβ icv injection or delays their appearance in Tg2576 mice. In both of our preclinical model of AD, behavioral protection was associated with synapse maintenance in hippocampus.Therefore, in situ long term CNTF delivery is an efficient preventive therapeutic strategy against toxicity and Aβ-linked cognitive disturbances. These results also suggest that encapsulated cells graft is a good way to deliver therapeutic molecules to the brain
79

Les astrocytes réactifs, des partenaires anti-agrégants dans la maladie de Huntington : identification des mécanismes impliqués dans le dialogue neurone-astrocyte / Reactive Astrocytes as Anti-Aggregation Partners in Huntington's Disease : Identification of Mechanisms Involved in the Neuron-Astrocyte Dialogue

Abjean, Laurene 09 April 2019 (has links)
La maladie de Huntington (MH) est une maladie neurodégénérative causée par une extension de répétitions du codon CAG dans le gène de la Huntingtine (Htt). Cette maladie est caractérisée par la mort des neurones striataux et la présence d’agrégats de Htt mutée (mHtt). De plus, au cours de la MH, les astrocytes, qui sont essentiels au bon fonctionnement neuronal, changent d’état et deviennent réactifs. La réactivité astrocytaire est caractérisée par des changements morphologiques et transcriptomiques mais l’impact fonctionnel de cette réactivité reste peu compris.Afin d’étudier le rôle des astrocytes réactifs dans la MH, nous avons utilisé des vecteurs viraux récemment développés par notre équipe, qui induisent ou bloquent la réactivité astrocytaire in vivo en ciblant la voie JAK2-STAT3. Nous avons montré que les astrocytes réactifs diminuent le nombre et la taille des agrégats de mHtt majoritairement présents dans les neurones. Ceci est associé à l’amélioration de plusieurs altérations neuronales observées dans ces modèles. Une analyse transcriptomique réalisée sur des astrocytes réactifs révèle des changements majeurs d’expression de gènes liés aux systèmes de protéostasie. De plus, l’activité du lysosome et du protéasome est augmentée dans les astrocytes réactifs de souris modèles de la MH. Nous montrons également que les astrocytes réactifs éliminent plus efficacement leurs propres agrégats de mHtt, suggérant qu’au cours de la MH, ces cellules pourraient dégrader plus efficacement la mHtt provenant des neurones. De plus, certaines protéines chaperonnes sont induites dans les astrocytes réactifs. En particulier, la co-chaperonne DNAJB1/Hsp40 est surexprimée dans les astrocytes réactifs et est retrouvée dans les exosomes isolés à partir de striata de souris MH. Des expériences de gain et perte de fonction suggèrent que cette chaperonne est impliquée dans les effets bénéfiques des astrocytes réactifs sur l’agrégation de la mHtt et l’état des neurones. Les astrocytes réactifs pourraient donc libérer des protéines anti-agrégantes qui favorise l’élimination de la mHtt dans les neurones.Notre étude montre que les astrocytes peuvent, en devenant réactifs au cours de la MH, acquérir des propriétés bénéfiques pour les neurones et favoriser, via un dialogue complexe avec les neurones, l’élimination des agrégats de mHtt. / Huntington’s disease (HD) is a hereditary neurodegenerative disease caused by an expansion of CAG codons in the Huntingtin gene. It is characterized by the death of striatal neurons and the presence of mutant Huntingtin (mHtt) aggregates. In pathological conditions, as in HD, astrocytes change and become reactive. Astrocyte reactivity is characterized by morphological and significant transcriptomic changes. Astrocytes are essential for the proper functioning of neurons but the functional changes associated with reactivity are still unclear.To better understand the roles played by reactive astrocytes in HD, we took advantage of our recently developed viral vectors that infect selectively astrocytes in vivo and either block or induce reactivity, through manipulation of the JAK2-STAT3 pathway. We used these vectors in two complementary mouse models of HD and found that reactive astrocytes decrease the number and the size of mHtt aggregates that mainly form in neurons. Reduced mHtt aggregation was associated with improvement of neuronal alterations observed in our mouse models of HD. A genome-wide transcriptomic analysis was performed on acutely sorted reactive astrocytes and revealed an enrichment in genes linked to proteolysis. Lysosomal and proteosomal activities were also increased in reactive astrocytes in HD mice. Moreover, we show that reactive astrocytes degrade more efficiently their own mHtt aggregates, suggesting that these cells could siphon mHtt away from neurons. Alternatively, several chaperones were induced in reactive astrocytes. In particular, the co-chaperone DNAJB1/Hsp40 was upregulated in reactive astrocytes and was present in exosomal fraction from HD mouse striatum. Loss and gain of function experiments suggest that this chaperone is involved in the beneficial effects of reactive astrocytes on mHtt aggregation and neuronal status. Therefore, reactive astrocytes could release anti-aggregation proteins that could promote mHtt clearance in neurons.Overall, our data show that astrocytes, by becoming reactive in HD, develop a protective response that involves complex bidirectional signaling with neurons to reduce mHtt aggregation.
80

Bedeutung nicht-kodierender RNAs im Immunsystem

Hösler, Nadine 19 June 2015 (has links)
Immer mehr Berichte deuten darauf hin, dass nicht-kodierende RNAs an der Regulation des Immunsystems beteiligt sind. In dieser Arbeit wurden nicht-kodierende RNAs identifiziert, die durch zwei unterschiedliche immunologische Prozesse in zwei verschiedenen Zelltypen reguliert wurden. Zum einen wurde das Transkriptom von Multiplen Myelom-Zellen in Abhängigkeit von der Interleukin 6-Stimulation untersucht. Dabei wurden einige sehr lange, IL 6-regulierte macroRNAs identifiziert, die STAIRs (STAT3-induced RNAs). Bei den STAIRs handelt es sich wahrscheinlich um funktionelle, kontinuierliche, nicht-kodierende macroRNAs, die im Zellkern angereichert sind. Einige STAIRs dienen eventuell zusätzlich oder ausschließlich als Primärtranskript für gespleißte, lange ncRNAs (lncRNAs), die weitere Funktionen in der Zelle ausüben können. Die STAIRs weisen eine große Bandbreite an Gewebsspezifität auf und bei den Untersuchungen in dieser Arbeit zeigten sich Hinweise, dass sie sich für verschiedene Krebserkrankungen als Biomarker eignen könnten. Die zweite Transkriptomanalyse wurde bei der Aktivierung naiver T Zellen durchgeführt. Dabei offenbarte sich, dass die Zellen bei diesem Prozess einen dramatischen Wechsel ihres Transkriptionsprogrammes vollziehen und eine Vielzahl nicht Protein-kodierender Gene reguliert werden. Es wurde die Regulation von ncRNAs, die bisher noch nicht im Zusammenhang mit T Zellen beschrieben wurden, beobachtet und erneut unbekannte, differentiell exprimierte Bereiche identifiziert. Im Anschluss wurde STAIR18, eine nicht-kodierende RNA, die durch die beiden untersuchten Signalwege reguliert wird, eingehender untersucht. Es zeigte sich, dass STAIR18 im menschlichen Genom dupliziert ist und beide Loci die gespleißte, lange ncRNA152 in diversen Varianten transkribieren. ncRNA152 ist hauptsächlich im Zytoplasma lokalisiert und befindet sich dort anscheinend in perinukleären Aggregaten. Die verschiedenen ncRNA152-Isoformen scheinen unter-schiedliche Funktionen auszuführen. Einerseits ist eine Wirkung als competing endogenous RNA wahrscheinlich. Eine weitere Aufgabe der ncRNA152 scheint darin zu bestehen, das STAT3-Primärtranskript zu stabilisieren oder dessen Prozessierung zu fördern.:1 Einleitung 1 1.1 Nicht-kodierende RNAs 1 1.1.1 Funktionen langer nicht-kodierender RNAs 2 1.1.2 Lange nicht-kodierende RNAs in Krebserkrankungen 4 1.2 Die Signaltransduktion von IL-6 und STAT3 5 1.2.1 Die IL-6/STAT3-Signalkaskade 5 1.2.2 Der Transkriptionsfaktor STAT3 7 1.2.3 Interleukin 6 und STAT3 in Krebserkrankungen 9 1.2.4 STAT3-regulierete nicht-kodierende RNAs 12 1.3 T-Zellen 13 1.3.1 T Zellaktivierung 14 1.3.2 Lange nicht-kodierende RNAs in T Zellen 16 1.4 Zielstellung 18 2 Material und Methoden 20 2.1 Bioinformatische Methoden 20 2.1.1 Evaluierung von Tiling Array-Daten 20 2.1.2 Evaluierung von Hochdurchsatz-Sequenzierungen 21 2.1.3 Auswertung von Mikroarray-Daten 21 2.1.4 DNA-Sequenzanalysen 22 2.1.5 Design von Oligonukleotiden 23 2.1.6 Statistische Auswertung 24 2.2 Molekularbiologische Methoden 25 2.2.1 Zellfraktionierung 25 2.2.2 Isolation von RNA 25 2.2.3 Reverse Transkription 26 2.2.4 Quantitative real-time PCR 27 2.2.5 Klonierung 29 2.3 Zellbiologische Methoden 36 2.3.1 Präparation primärer T-Helferzellen 36 2.3.2 Zellkultur und Stimulation eukaryontischer Zellen 38 2.3.3 Durchflusszytometrie 40 2.3.4 Transiente Transfektion eukaryontischer Zellen 42 2.3.5 Reportergenanalysen 44 2.3.6 Fluoreszenz in situ Hybridisierung 45 2.3.7 Gewebe- und Patientenproben 48 3 Ergebnisse 50 3.1 Identifizierung und Charakterisierung neuer STAT3-regulierter ncRNA-Gene 50 3.1.1 Genomweite Untersuchung STAT3-regulierter ncRNAs 50 3.1.2 Validierung der IL-6-Tiling Array-Daten 65 3.1.3 Intrazelluläre Lokalisation der STAIRs 67 3.1.4 Expressionsprofile der STAIRs 68 3.2 Identifizierung regulierter ncRNA-Gene während der T Zellaktivierung 72 3.2.1 Etablierung der in vitro Aktivierung primärer T Zellen 72 3.2.2 Genomweite Untersuchung regulierter RNAs während der T-Zellaktivierung 74 3.2.3 Validierung der T-Zellaktivierungs-Genomdaten 83 3.3 Untersuchung der nicht-kodierenden RNA STAIR18 / ncRNA152 83 3.3.1 STAIR18 ist im humanen Genom dupliziert 84 3.3.2 Von beiden STAIR18-Loci werden gespleißte Transkripte generiert 86 3.3.3 Regulation der ncRNA152 90 3.3.4 Untersuchung des STAIR18/ncRNA152-Promotors 96 3.3.5 Intrazelluläre Lokalisation von STAIR18 und ncRNA152 101 3.3.6 Überexpression der ncRNA152 in XG-1-Zellen 106 3.3.7 Knockdown der ncRNA152 in XG-1-Zellen 107 3.3.8 Identifizierung putativer Zielgene der ncRNA152 109 4 Diskussion 111 4.1 IL 6/STAT3 regulierte macroRNAs 111 4.1.1 Charakterisierung der STAIRs 114 4.1.2 STAIRS als potentielle Biomarker 121 4.2 Regulation von lncRNAs während der T Zellaktivierung 122 4.3 Untersuchung von STAIR18/ncRNA152 128 4.3.1 Regulation von STAIR18 und der ncRNA152 129 4.3.2 Lokalisation von STAIR18 und der ncRNA152 130 4.3.3 Manipulation der ncRNA152-Expression 131 4.3.4 Bedeutung der ncRNA152 133 5 Zusammenfassung 135 6 Summary 138 7 Literaturverzeichnis 141 8 Anhang 153 Danksagung 168 Publikationen 16969 Selbstständigkeitserklärung 170

Page generated in 0.0573 seconds